id	metarevistapublica_asoneumocito_revistacolombianadeneumologia_28_article_547
record_format	ojs
spelling	Lung cancer represented the second leading cause of cancer and the leading cause of cancer mortality in the United States by 2020. In 2016, 538,000 lung cancer cases were reported, with 80,775 men and 68,096 women dying in the same year. The five-year survival rate of 15.6 % in 2011 rose to 19.4 % in 2019, probably associated with a decrease in smokers, mainly due to advances in targeted pharmacological therapies and the development of immunotherapies. Pulmonary adenocarcinoma, particularly in young, nonsmoking women, has shown an increased incidence. However, survival in this population has had significant advances associated with a better, updated understanding of identifiable biological and genetic mechanisms in lung cancer and a better classification of these tumors into types and subtypes. Numerous advances in immunohistochemical techniques (in the diagnosis and classification of lung cancer and selection of cases for molecular analysis) and the knowledge of genomic alterations associated with various lung cancer types have changed their treatment approach, especially in advanced stages of tumorigenesis. Oncogenes and tumor suppressor genes have been identified, making possible the development of novel therapeutic agents with a well-defined, focused target and immunotherapy as an additional therapeutic option for this pathology. This review is intended to provide a straightforward guide to the tumor architecture (immunohistochemistry and molecular analysis) of lung cancer in its most common types. Casallas Gómez, Alvaro cáncer pulmonar adenocarcinoma inmunohistoquímica biología tumoral genética biopsias líquidas lung cancer adenocarcinoma immunohistochemistry tumor biology genetics liquid biopsies 33 1 Artículo de revista Journal article 2021-10-13T16:17:57Z 2021-10-13T16:17:57Z 2021-10-13 application/pdf Asociación Colombiana de Neumología y Cirugía de Tórax Revista Colombiana de Neumología 0121-5426 2538-9513 https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/547 10.30789/rcneumologia.v33.n1.2021.547 https://doi.org/10.30789/rcneumologia.v33.n1.2021.547 spa https://creativecommons.org/licenses/by-nc-sa/4.0/ 6 18 https://revistas.asoneumocito.org/index.php/rcneumologia/article/download/547/475 info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_dcae04bc http://purl.org/redcol/resource_type/ARTREV info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Text Publication
institution	ASOCIACION COLOMBIANA DE NEUMOLOGIA Y CIRUGIA DE TORAX
thumbnail	https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADENEUMOLOGIAYCIRUGIADETORAX/logo.png
country_str	Colombia
collection	Revista Colombiana de Neumología
description_eng	Lung cancer represented the second leading cause of cancer and the leading cause of cancer mortality in the United States by 2020. In 2016, 538,000 lung cancer cases were reported, with 80,775 men and 68,096 women dying in the same year. The five-year survival rate of 15.6 % in 2011 rose to 19.4 % in 2019, probably associated with a decrease in smokers, mainly due to advances in targeted pharmacological therapies and the development of immunotherapies. Pulmonary adenocarcinoma, particularly in young, nonsmoking women, has shown an increased incidence. However, survival in this population has had significant advances associated with a better, updated understanding of identifiable biological and genetic mechanisms in lung cancer and a better classification of these tumors into types and subtypes. Numerous advances in immunohistochemical techniques (in the diagnosis and classification of lung cancer and selection of cases for molecular analysis) and the knowledge of genomic alterations associated with various lung cancer types have changed their treatment approach, especially in advanced stages of tumorigenesis. Oncogenes and tumor suppressor genes have been identified, making possible the development of novel therapeutic agents with a well-defined, focused target and immunotherapy as an additional therapeutic option for this pathology. This review is intended to provide a straightforward guide to the tumor architecture (immunohistochemistry and molecular analysis) of lung cancer in its most common types.
author	Casallas Gómez, Alvaro
spellingShingle	Casallas Gómez, Alvaro cáncer pulmonar adenocarcinoma inmunohistoquímica biología tumoral genética biopsias líquidas lung cancer adenocarcinoma immunohistochemistry tumor biology genetics liquid biopsies
author_facet	Casallas Gómez, Alvaro
topicspa_str_mv	cáncer pulmonar adenocarcinoma inmunohistoquímica biología tumoral genética biopsias líquidas
topic	cáncer pulmonar adenocarcinoma inmunohistoquímica biología tumoral genética biopsias líquidas lung cancer adenocarcinoma immunohistochemistry tumor biology genetics liquid biopsies
topic_facet	cáncer pulmonar adenocarcinoma inmunohistoquímica biología tumoral genética biopsias líquidas lung cancer adenocarcinoma immunohistochemistry tumor biology genetics liquid biopsies
citationvolume	33
citationissue	1
publisher	Asociación Colombiana de Neumología y Cirugía de Tórax
ispartofjournal	Revista Colombiana de Neumología
source	https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/547
language	spa
format	Article
rights	https://creativecommons.org/licenses/by-nc-sa/4.0/ info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2
type_driver	info:eu-repo/semantics/article
type_coar	http://purl.org/coar/resource_type/c_6501
type_version	info:eu-repo/semantics/publishedVersion
type_coarversion	http://purl.org/coar/version/c_970fb48d4fbd8a85
type_content	Text
publishDate	2021-10-13
date_accessioned	2021-10-13T16:17:57Z
date_available	2021-10-13T16:17:57Z
url	https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/547
url_doi	https://doi.org/10.30789/rcneumologia.v33.n1.2021.547
issn	0121-5426
eissn	2538-9513
doi	10.30789/rcneumologia.v33.n1.2021.547
citationstartpage	6
citationendpage	18
url2_str_mv	https://revistas.asoneumocito.org/index.php/rcneumologia/article/download/547/475
_version_	1811200725997322240

.

Código QR

Estadísticas y Métricas Alternativas

Títulos similares